Asciminib: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 2, p. 219, doi. 10.1007/s40265-021-01662-3
- By:
- Publication type:
- Article
Works matching IS 00126667 AND DT 2022 AND VI 82 AND IP 2
Results: 9
1
2
Gastrointestinal Dysfunction in Parkinson's Disease.
- Published in:
- Drugs, 2022, v. 82, n. 2, p. 169, doi. 10.1007/s40265-021-01664-1
- By:
- Publication type:
- Article
3
Somatrogon: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 2, p. 227, doi. 10.1007/s40265-021-01663-2
- By:
- Publication type:
- Article
4
Current Treatment of Chronic Lymphocytic Leukemia: The Diminishing Role of Chemoimmunotherapy.
- Published in:
- Drugs, 2022, v. 82, n. 2, p. 133, doi. 10.1007/s40265-021-01657-0
- By:
- Publication type:
- Article
5
Envafolimab: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 2, p. 235, doi. 10.1007/s40265-022-01671-w
- By:
- Publication type:
- Article
6
Third-Generation Antiseizure Medications for Adjunctive Treatment of Focal-Onset Seizures in Adults: A Systematic Review and Network Meta-analysis.
- Published in:
- Drugs, 2022, v. 82, n. 2, p. 199, doi. 10.1007/s40265-021-01661-4
- By:
- Publication type:
- Article
7
Treatment of Non-Infectious Corneal Injury: Review of Diagnostic Agents, Therapeutic Medications, and Future Targets.
- Published in:
- Drugs, 2022, v. 82, n. 2, p. 145, doi. 10.1007/s40265-021-01660-5
- By:
- Publication type:
- Article
8
Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy.
- Published in:
- Drugs, 2022, v. 82, n. 2, p. 109, doi. 10.1007/s40265-021-01656-1
- By:
- Publication type:
- Article
9
New Therapeutic Horizons in Chronic Kidney Disease: The Role of SGLT2 Inhibitors in Clinical Practice.
- Published in:
- Drugs, 2022, v. 82, n. 2, p. 97, doi. 10.1007/s40265-021-01655-2
- By:
- Publication type:
- Article